Nektar Therapeutics Inc. (NKTR)
NASDAQ · Healthcare
Nektar Therapeutics Inc. EBITDA 2009–2025
Nektar Therapeutics Inc. annual/quarterly ebitda history and growth rate from 2009 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Nektar Therapeutics Inc. ebitda for the quarter ending March 31, 2026 was -38.9 M, a 11.80% decrease year-over-year.
- Nektar Therapeutics Inc. ebitda for the twelve months ending March 31, 2026 was -249.2 M, a 46.45% decrease year-over-year.
- Nektar Therapeutics Inc. annual ebitda for 2025 was -139.1 M, a 37.57% increase from 2024.
- Nektar Therapeutics Inc. annual ebitda for 2024 was -101.1 M, a 60.61% decrease from 2023.
- Nektar Therapeutics Inc. annual ebitda for 2023 was -256.7 M, a 29.48% decrease from 2022.
- Nektar Therapeutics Inc. annual ebitda for 2022 was -364.0 M.
EBITDA
TRAILING 12 MONTHS · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Nektar Therapeutics Inc. EBITDA — FAQ
Nektar Therapeutics Inc. (NKTR) ebitda over the last 17 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see NKTR's ebitda history?
The chart and table above show Nektar Therapeutics Inc.'s ebitda by year and by quarter, including the growth rate.